CONCUSSION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In September 2024, Nihon Kohden, a global leader in medical device innovation, announced that its Board of Directors approved the acquisition of a 71.4% stake in NeuroAdvanced Corp. (NAC), the parent company of Ad-Tech Medical Instrument Corporation in the U.S. This strategic move will make both NAC and Ad-Tech consolidated subsidiaries of Nihon Kohden, as their respective capital will account for 10% or more of Nihon Kohden’s total capital.
• In July 2024, Oculogica, a neuro-diagnostic company specializing in eye-tracking technology, announced that Health Canada approved its EyeBOX concussion diagnostic device. This approval allows healthcare professionals across Canada to utilize EyeBOX for swift and accurate assessment of mild traumatic brain injuries (mTBIs).
• In April 2024, Abbott, a global healthcare company, received the U.S. Food and Drug Administration (FDA) clearance for its i-STAT TBI cartridge for use with whole blood. This advancement enables doctors to evaluate patients with suspected concussions at the bedside, delivering lab-quality results in just 15 minutes. Previously, TBI assessment tests required plasma or serum samples to be sent to a laboratory for processing and analysis.
• In December 2023, Integra LifeSciences Holdings Corporation, a leading global provider of regenerative technologies and neurosurgical solutions, finalized a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a subsidiary of Johnson & Johnson MedTech, for USD 275 million in cash at closing, with customary purchase price adjustments. Additionally, there is a provision for an extra USD 5 million contingent upon meeting certain regulatory milestones.